Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market Forecasts Report 2025-2030 Boehringer Ingelheim And Fibrogen Lead By Driving Innovations In Pharmacological And Diagnostic Advancements

(MENAFN- GlobeNewsWire - Nasdaq) The Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market is projected to grow from USD 5.917 billion in 2025 to USD 8.549 billion by 2030, with a CAGR of 7.64%. This study provides detailed insights into market dynamics, segmentation, and competitive strategies, highlighting key players like Boehringer Ingelheim and FibroGen.

Dublin, Sept. 05, 2025 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering.
The Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market is expected to grow from USD 5.917 billion in 2025 to USD 8.549 billion in 2030, at a CAGR of 7.64%.

The Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study provides a comprehensive analysis of the global idiopathic pulmonary fibrosis (IPF) diagnostic and treatment market, offering industry experts critical insights into market trends, therapeutic advancements, and competitive strategies shaping this vital healthcare sector. It includes robust analyses such as Porter's Five Forces Analysis, Industry Value Chain Analysis, and market share evaluations, alongside strategic recommendations and regulatory insights to help stakeholders capitalize on growth opportunities in this critical market.

Competitive Environment and Analysis
In the competitive intelligence section of the Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study, key players are highlighted for their strategic initiatives to strengthen market presence.

Boehringer Ingelheim
has recently advanced its nintedanib portfolio by securing regulatory approvals for expanded indications, enhancing its application in IPF treatment across hospitals and clinics. This development reinforces Boehringer Ingelheim's leadership in pharmacological solutions. Similarly,

FibroGen, Inc.
has progressed its clinical pipeline through a strategic collaboration to develop novel diagnostic testing methods for early IPF detection, targeting improved patient outcomes in the healthcare sector. The study also covers market share analysis, mergers, acquisitions, and a competitive dashboard to provide a holistic view of the competitive landscape.
Conclusion
With leading players like Boehringer Ingelheim and FibroGen, Inc. driving innovation in pharmacological and diagnostic advancements, the Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Study empowers stakeholders to stay competitive in this dynamic and rapidly evolving industry.
Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

Key Attributes:

Report Attribute	Details
No. of Pages	144
Forecast Period	2025 - 2030
Estimated Market Value (USD) in 2025	$5.92 Billion
Forecasted Market Value (USD) by 2030	$8.55 Billion
Compound Annual Growth Rate	7.6%
Regions Covered	Global

Business Landscape

• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis
• Industry Value Chain Analysis
• Policies and Regulations
• Strategic Recommendations

Companies Featured

• Roche Holding AG
• Boehringer Ingelheim
• AdAlta
• FibroGen, Inc.
• United Therapeutics
• Galecto Biotech

Market Segments

By Type

• Diagnostic Testing
• Pharmacological Drugs
• Surgical Treatment

By Drug Type

• Pirfenidone
• Nintedanib
• Others

By Route of Administration

• Oral
• Parenteral

BY End-Use

• Hospitals and Clinics
• Ambulatory Surgical Centers
• Others

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN05092025004107003653ID1110021302